Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Eclinicalmedicine|May 8, 2023
Cognitive adverse events in patients with lung cancer treated with checkpoint inhibitor monotherapy: a propensity score-matched analysisYifei Ma, Nianqi Liu, Yanqi Wang, et al.
Eclinicalmedicine|May 30, 2024
Dietary supplement for mood symptoms in early postpartum: a double-blind randomized placebo controlled trialJeffrey H Meyer, ZhaoHui Wang, Apitharani Santhirakumar, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 2, 2024
Cerebral <sup>18</sup>F-FDG PET/CT Metabolism as Diagnostic Signature for Central Nervous System Toxicity After Immune Checkpoint Blockade Cancer TreatmentYifei Ma, Jiling Zeng, Fadian Ding, et al.
Nature Communications|December 13, 2023
A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesityLinong Ji, Hongwei Jiang, Zhifeng Cheng, et al.
JAMA|June 7, 2026
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical TrialLeili Gao, Hongwei Jiang, Hanqing Cai, et al.
The New England Journal of Medicine|May 27, 2025
Once-Weekly Mazdutide in Chinese Adults with Obesity or OverweightLinong Ji, Hongwei Jiang, Yan Bi, et al.
Frontiers in Immunology|April 24, 2023
Thyroid function and associated mood changes after COVID-19 vaccines in patients with Hashimoto thyroiditisYifei Ma, Jiling Zeng, Yongluo Jiang, et al.
The Lancet. Rheumatology|January 17, 2024
IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trialHuji Xu, Zhijun Li, Jian Wu, et al.
Nature Communications|February 15, 2022
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)Jianming Xu, Yi Li, Qingxia Fan, et al.
Cancer Communications (London, England)|November 7, 2022
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)Yuankai Shi, Lin Wu, Xinmin Yu, et al.
Pageof 9